The impact of the completed human genome sequence on the development of novel therapeutics for human disease.

With the official completion of the Human Genome Project in April 2003, we have both the opportunity and the imperative to translate this unprecedented scientific accomplishment into tangible improvements in human health. Medical benefits from the genome will come in stages and can be conceptualized as occurring in three areas: improved understanding of disease causation at the molecular level, improved diagnosis and disease classification based on genetic profiles, and new therapeutics based on targets identified in the genome. These improvements will require increased physician understanding of genetic principles applied to common diseases.

[1]  L. Staudt,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[2]  F. Collins,et al.  The Human Genome Project: Lessons from Large-Scale Biology , 2003, Science.

[3]  Nancy F. Hansen,et al.  Comparative analyses of multi-species sequences from targeted genomic regions , 2003, Nature.

[4]  F. Collins,et al.  Welcome to the genomic era. , 2003, The New England journal of medicine.

[5]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[6]  M. Sarwal,et al.  Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. , 2003, The New England journal of medicine.

[7]  F. Crick,et al.  Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid , 1953, Nature.

[8]  David G. Behm,et al.  Deletion of the UT receptor gene results in the selective loss of urotensin‐II contractile activity in aortae isolated from UT receptor knockout mice , 2003, British journal of pharmacology.

[9]  J. Bell,et al.  The double helix in clinical practice , 2003, Nature.

[10]  N. Ditsch,et al.  Immunotherapy: new options in breast cancer treatment , 2003, Expert review of anticancer therapy.

[11]  H. Judson.  "The greatest surprise for everyone"--notes on the 50th anniversary of the double helix. , 2003, The New England journal of medicine.

[12]  K. Chien,et al.  A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. , 2003, Human molecular genetics.

[13]  E. Zerhouni.  The NIH Roadmap , 2003, Science.

[14]  M. West,et al.  Gene expression predictors of breast cancer outcomes , 2003, The Lancet.

[15]  C. Perou,et al.  Molecular portraits and the family tree of cancer , 2002, Nature Genetics.

[16]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[17]  F. Collins,et al.  A vision for the future of genomics research , 2003, Nature.

[18]  J. Drews.  Drug discovery: a historical perspective. , 2000, Science.

[19]  S. Gabriel,et al.  The Structure of Haplotype Blocks in the Human Genome , 2002, Science.

[20]  S. Salzberg,et al.  The genome sequence of Bacillus anthracis Ames and comparison to closely related bacteria , 2003, Nature.

[21]  Jon Emery,et al.  Genetics education for primary-care providers , 2002, Nature Reviews Genetics.

[22]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[23]  J. Drews,et al.  Drug Development: The role of innovation in drug development , 1997, Nature Biotechnology.

[24]  B. Druker,et al.  Recent advancements in the treatment of chronic myelogenous leukemia. , 2002, Annual review of medicine.

[25]  R. Strausberg,et al.  From Knowing to Controlling: A Path from Genomics to Drugs Using Small Molecule Probes , 2003, Science.

[26]  James Scott,et al.  Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats , 1999, Nature Genetics.

[27]  T. Peakman,et al.  Delivering the power of discovery in large pharmaceutical organizations. , 2003, Drug discovery today.

[28]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[29]  Colin N. Dewey,et al.  Initial sequencing and comparative analysis of the mouse genome. , 2002 .

[30]  J. Peiris,et al.  Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome , 2003, The Lancet.

[31]  C. Magee,et al.  The growing problem of chronic renal failure after transplantation of a nonrenal organ. , 2003, The New England journal of medicine.

[32]  J. Alper.  Biotech Thinking Comes to Academic Medical Centers , 2003, Science.

[33]  T. Gura.  After the Gold Rush: Gene Firms Reinvent Themselves , 2002, Science.

[34]  V A McKusick,et al.  Mapping and sequencing the human genome. , 1989, The New England journal of medicine.

[35]  L. Lesko,et al.  Microarray data—the US FDA, industry and academia , 2003, Nature Biotechnology.

[36]  H. Kubinyi.  Drug research: myths, hype and reality , 2003, Nature Reviews Drug Discovery.

[37]  A. Telenti,et al.  Individualising HIV treatment—pharmacogenetics and immunogenetics , 2002, The Lancet.

[38]  Pat Levitt,et al.  Molecular Characterization of Schizophrenia Viewed by Microarray Analysis of Gene Expression in Prefrontal Cortex , 2000, Neuron.

[39]  Syed Mohsin,et al.  Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer , 2003, The Lancet.

[40]  M. Khoury,et al.  Population screening in the age of genomic medicine. , 2003, The New England journal of medicine.

[41]  D. Gerhold,et al.  Better therapeutics through microarrays , 2002, Nature Genetics.

[42]  Jonathan C. Cohen,et al.  An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing , 2001, Science.

[43]  K. Wagner.  Genetic diseases of muscle. , 2002, Neurologic clinics.

[44]  Ash A. Alizadeh,et al.  Towards a novel classification of human malignancies based on gene expression patterns , 2001, The Journal of pathology.

[45]  M. Oscarson.  Pharmacogenetics of Drug Metabolising Enzymes: Importance for Personalised Medicine , 2003, Clinical chemistry and laboratory medicine.

[46]  Laura Scott,et al.  Recurrent de novo point mutations in lamin A cause Hutchinson–Gilford progeria syndrome , 2003, Nature.

[47]  N. Holtzman,et al.  Will genetics revolutionize medicine? , 2000, The New England journal of medicine.

[48]  D. Stoppa-Lyonnet,et al.  IMPACT OF GENE PATENTS ON THE COST-EFFECTIVE DELIVERY OF CARE: THE CASE OF BRCA1 GENETIC TESTING , 2003, International Journal of Technology Assessment in Health Care.

[49]  M. Branca.  Putting Gene Arrays to the Test , 2003, Science.

[50]  Denis Noble,et al.  Will genomics revolutionise pharmaceutical R&D? , 2003, Trends in Biotechnology.

[51]  H. Sarau,et al.  Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 , 1999, Nature.

[52]  J. Drews.  Genomic sciences and the medicine of tomorrow , 1996, Nature Biotechnology.